Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

New England Journal of Medicine
December 17, 2020 Vol. 383 No. 25
http://www.nejm.org/toc/nejm/medical-journal

 

Original Article
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults E.J. Anderson and Others
Conclusions
In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461. opens in new tab.)

New England Journal of Medicine
December 17, 2020 Vol. 383 No. 25
http://www.nejm.org/toc/nejm/medical-journal

 

Original Article
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults E.J. Anderson and Others
Conclusions
In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461. opens in new tab.)